FIM
GALT icon

Freedom Investment Management’s Galectin Therapeutics GALT Stock Holding History

Freedom Investment Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-37,557
Closed -$54K – 856
2016
Q1 		$54K Sell
37,557
-8,345
-18% -$11.2K ﹤0.01% 809
2015
Q4 		$75K Buy
45,902
+36,577
+392% +$83.8K 0.01% 760
2015
Q3 		$832K Sell
9,325
-36,398
-80% -$85.8K 0.08% 197
2015
Q2 		$125K Sell
45,723
-3,668
-7% -$11.1K 0.01% 652
2015
Q1 		$165K Sell
49,391
-6,328
-11% -$22.6K 0.02% 600
2014
Q4 		$193K Buy
55,719
+39,395
+241% +$174K 0.03% 546
2014
Q3 		$82K Buy
16,324
+781
+5% +$6.08K 0.01% 485
2014
Q2 		$215K Buy
15,543
+419
+3% +$5.22K 0.04% 442
2014
Q1 		$232K Buy
15,124
+2,203
+17% +$31.4K 0.05% 355
2013
Q4 		$104K Buy
12,921
+982
+8% +$9.07K 0.03% 419
2013
Q3 		$119K Buy
+11,939
New +$80.5K 0.03% 357

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Freedom Investment Management's GALT Position: Q2 2016 in Review

Freedom Investment Management sold out of Galectin Therapeutics (GALT) in Q2 2016, closing a stake of 37,557 shares — an estimated $54K sold.

Freedom Investment Management first reported a position in GALT in Q3 2013 and held it in 11 quarters. The position peaked at $832K in Q3 2015. 51 funds tracked by Wall St. Rank hold GALT as of Q2 2016.

  • Freedom Investment Management reported no remaining Galectin Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Freedom Investment Management sold 37,557 Galectin Therapeutics shares in Q2 2016, an estimated $54K.
  • Freedom Investment Management first reported a position in Galectin Therapeutics in Q3 2013 and held it in 11 quarters.
  • Freedom Investment Management's Galectin Therapeutics position peaked at $832K in Q3 2015.
  • 51 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2016.

Based on Freedom Investment Management's 13F filing for Q2 2016, filed 14 Jul 2016.